Background/Aims: Accumulating evidence revealed that microRNAs (miRNAs) have been demonstrated as critical molecules in tumor development and progression. MiR-26a, located in a fragile chromosomal region associated with various human cancer, has been reported to be involved in regulating various cellular process, such as proliferation, apoptosis and invasion through targeting multiple oncogene. Docetaxel-mediated chemotherapy has been applied in improving the survival and prognosis of patients with advanced lung adenocarcinoma (LAD). However, chemoresistance remains a major impediment to clinical application of this agent. It has been presented that decreased miR-26a expression lead to cisplatin resistance and promoted growth and migration in human lung cancer. Enhancer of zeste homolog 2 (EZH2) is the target of miR-26a. The present study aimed to investigate the function of miR-26a/EZH2 in Methods: MiR-26a and EZH2 expression levels in the dcetaxel-insensitive groups (n = 19) and the docetaxel-sensitive groups (n = 18) were cell transwell assays and western blotting were performed to assess the effects of miR-26a on proliferation, apoptosis and epithelial-to-mesenchymal (EMT) phenotypes in docetaxelresistant LAD cells in vitro. Xenograft transplantation, immunohistochemistry, tunel assays and western blotting assays were employed to demonstrate the role of miR-26a in docetaxelresistant LAD cells in vivo. increased the apoptosis rate and reversed EMT to MET of docetaxel-resistant LAD cells both in vivo the function of miR-26a exerts in docetaxel-resistant LAD cells is through targeting EZH2. Conclusions: Our data revealed that overexpression of miR-26a in docetaxel-resistant LAD cells could decrease the proliferation, increase the apoptosis rate and reverse EMT to MET of docetaxel-resistant LAD cells both in vivo and vitro and such function is partially exerted via downregulating EZH2. MiR-26a/EZH2 signal pathway makes contribute to the malignant phenotype of docetaxel-resistant of LAD cells which indicated that miR-26a exerts pivotal functions in the molecular etiology of chemoresistant lung adenocarcinoma.
MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of DoctaxelResistant Lung Adenocarcinoma Cells through Targeting EZH2
Non-small cell lung cancer (NSCLC), is the predominant form of lung cancer, among which, LAD is the most common histological type. LAD, always diagnosed at advanced stage, has been documented as the leading cause of cancer-related deaths [1] . Despite the development of molecular mechanisms underlying LAD has been made and treatments for LAD have been improved, the overall survival time is still limited [2] . The current therapies for advanced LAD mainly include surgery, radiotherapy, chemotherapy, local treatments and targeted therapies [3] . Docetaxel-mediated chemotherapy has been applied in improving the survival and prognosis of patients with advanced LAD. However, chemoresistance remains a major impediment to clinical application of this agent. Cells resistant to chemotherapy always exert more malignant behaviors, such as obtain a higher proliferative ability and stronger capability for invasion and metastasis. The mechanism underlying the malignant phenotype has not been fully cleared. Therefore, investigating the mechanism might be favor to explore new treatment strategies for LAD patients with chemoresistance.
MicroRNAs, a class of endogenous, small (18-25 nucleotides) non-coding RNAs, exert their functions by directly binding to the 3'-untranslated regions (3'UTR) of the target messenger RNAs, causing the degradation of the mRNA or translational inhibition of functional proteins [4, 5] . Emerging evidences show that alteration of microRNAs is involved in cancer initial and progression [6] [7] [8] [9] [10] [11] [12] . MicroRNA-26a is commonly dysregulation in diverse cancers, and involves in various biological processes, including proliferation, migration, invasion, angiogenesis and metabolism, via targeting multiple mRNAs. Besides, it has been revealed that decreased miR-26a expression could cause cisplatin resistance and promote growth and migration in human lung cancer [13, 14] . Thus, miR-26a might be involved in the malignant phenotype acquisition of docetaxel-resistant LAD cells.
Enhancer of zeste homolog 2 (EZH2) is the target of miR-26a. It has been demonstrated that miR-26a/EZH2 signal pathway contributes to the formation of EMT in HCC [15] . And down-expression of EZH2 could enhance the cisplatin-induced apoptosis in Osteosarcoma cell [16] . However, whether EZH2 contributes to the malignant phenotype acquisition of docetaxel-resistant LAD cells remains unknown. In the present study, we aimed to explore the functional role of miR-26a and EZH2 in the malignant phenotype acquisition of docetaxelresistant LAD cells.
Material and Methods

Patients
A total of 37 LAD tissues were obtained from patients diagnosed with advanced LAD in Department of Medical Oncology, Jinling Hospital (Nanjing, PR China) between March 2009 and September 2010. All the following criteria were met: a histological diagnosis of primary LAD with at least one measurable lesion; 2 and cisplatin 100 mg/m or docetaxel 75 mg/m 2 and carboplatin area under the curve 6 mg/mL/min administered every 3 weeks for a maximum of 5 cycles. Tissue samples were divided into "sensitive" (complete or partial response) (n = 18) and "insensitive" (n = 19) (stable or progressive disease) groups based on the patient responses assessed by medical image analysis and detection of serum tumor markers after 4 or 5 cycles of docetaxelbased chemotherapy. The research protocol was reviewed and approved by the Ethical Committee and Institutional Review Board of Jinling Hospital, and written informed consent was obtained from each patient included in the study.
Cell lines
Two human LAD cell lines SPC-A1 and H1299 were purchased from the Tumor Cell Bank of Chinese Academy of Medical Science (Shanghai, China) and the docetaxel-resistant LAD cells (SPC-A1/DTX and H1299/DTX) derived from parental SPC-A1 and H1299 cells, respectively, were established and preserved
Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
Total RNA from cells was isolated with Trizol reagent (Invitrogen, CA, USA) according to the manufacturer's protocol. Reverse transcription was performed with PrimeScript RT reagent Kit (Takara, Japan) according to the manufacturer's instructions. qRT-PCR was performed with SYBR Prime Script RT-PCR Kits (Takara, Japan) based on the manufacturer's instructions. The miR-26a or EZH2 level was calculated with the 2 method which were normalized to U6 rRNA or GAPDH mRNA, respectively. All assays were performed in triplicate. The expression levels were relative to the fold change of the corresponding controls
Cell transfection
Transfections with pcDNA3.1/EZH2, pcDNA3.1/miR-26a, siRNA/EZH2 (all obtained from GenePharma, Shanghai, China) and miR-26a mimics and inhibitor (all obtained from ABM, Canada) were performed using Lipofectamine 2000 (Invitrogen, USA), according to the manufacturer's protocol.
Dual luciferase reporter assay pmirGLO, pmirGLO-EZH2-wt or pmirGLO-EZH2-mut (miR-26a) was co-transfected with miR-26a mimics or miR-NC into SPC-A1/DTX cells by Lipofectamine-mediated gene transfer. The relative luciferase activity was normalized to Renilla luciferase activity 48h after transfection. The data were relative to the Colony formation assay Cells (500 cells/ well) with or without transfection were plated in 6-well plates and incubated in RPMI number of visible colonies was counted manually. All samples were assayed in triplicate.
Flow cytometric analysis of apoptosis
Kits (BD Biosciences, USA), according to the manufacturer's instructions. All samples were assayed in triplicate.
Wound healing assays
Cell migration capacity was calculated by wound healing assay. 2 × 10 5 cells with or without in serum-free medium and incubated in regular medium. Wounds were observed at 0 and 48 h. The cell migration distance was calculated by subtracting the wound width at each time point from the wound width at the 0h time point. Three independent assays were assayed. a microscope. Three independent experiments were carried out.
Western bolt analysis and antibodies
Protein loading was estimated using mouse anti-GAPDH monoclonal antibody. The membranes were blotted 
TUNEL assay
Apoptosis in transplanted-tumor tissues was detected by TUNEL method. The TUNEL assay was performed according to the guidelines recommended by the TUNEL assay kit (KeyGen, Nanjing, China).
Statistical analysis
Data are shown as the means ± standard error of at least three independent experiments. The SPSS 17.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Two group comparisons were performed with a Student t test. Multiple group comparisons were analyzed with one-way ANOVA. All expression levels in 37 cases of LAD tissues was analyzed by Spearman's correlation analysis. P < 0.05 was
Results
MiR-26a is down-expression in human docetaxel-insensitive LAD tissues and docetaxelresistant cell lines
A total of 37 cases of clinical LAD tissues were obtained from patients at advanced stage and divided into ''sensitive'' (complete or partial response) and ''insensitive'' (stable or progressive disease) groups in response to the docetaxel-based chemotherapies. MiR-26a 
MiR-26a is associated with proliferation, apoptosis, cell cycle and EMT of LAD cells
To investigate the biological functions of miR-26a on proliferation, apoptosis and EMT of LAD cells, H1299 (and SPC-A1) cells or H1299/DTX (and SPC-A1/DTX) cells were transfected with mirR-26a inhibitor or miR-26a mimics, respectively, using anti-miR-NC or down-regulated of miR-26a in H1299 and SPC-A1 cells increased the colony formation rate. While, weaken proliferation ability were observed in miR-26a transfected H1299/DTX and analysis of apoptosis was performed to detect the function of miR-26a on apoptosis in LAD rate of H1299 and SPC-A1 cells. On the contrary, compared with negative controls, forced expression of miR-26a caused an obviously increase in apoptosis rate in H1299/DTX or increased migratory capacity of H1299 and SPC-A1 cells transfected with miR-26a inhibitor, and decreased migratory potential was observed in H1299/DTX and SPC-A1/DTX cells the relationship between miR-26a and EZH2, we examined the expression level of EZH2 in response to dysregulated miR-26a expression in H1299/DTX and SPC-A1/DTX cells and its correlated with that of miR-26a, and up-regulated miR-26a could reduce the expression of EZH2 in protein level. To further validate the regulatory relationship between miR-26a reduced the luciferase activity of wild-type (WT) EZH2 reporter vector but not that of empty 26a-targeting gene.
EZH2 is associated with proliferation, apoptosis, cell cycle and EMT of LAD cells
Due to the previously reported facilitates proliferation, inhibits apoptosis and down-regulates E-cadherin expression of EZH2 [25] [26] [27] [28] , we transfected our two parental cells (H1299 and SPC-A1)with pcDNA3.1/EZH2 and two docetaxel-resistant LAD cells (H1299/DTX, SPC-A1/DTX) with EZH2 small interfering RNA (siRNA) to explore whether agent. Cells resistant to chemotherapy always obtain enhanced proliferation ability and stronger metastasis capacity. Docetaxle-resistant LAD cells (H1299/DTX and SPC-A1/DTX) established previously by our lab also presents a higher degree malignant than the parental cells. Investigating the underlying mechanism of this phenomenon is essential for clinical treatment of LAD patients.
MiRNAs composed of 20-22 non-coding nucleotides are associated with multiple cellular processes and diseases by directly binding to the 3'-UTR of the target mRNAs. Abnormal expression of miRNA has been reported in many cancers, for instance, let-7c function as a metastasis suppressor in colorectal cancer by targeting MMP11 and PBX3, and miR-29 can regulate the expression of long non-coding RNA gene MEG3 in HCC [29, 30] . Therefore, miRNAs represent a promising new family of targets in the current era of that miR-26a dysregulation in diverse diseases. MiR-26a is located in 3p23, which is a fragile chromosomal region associated with various human cancers [39] [40] [41] [42] [43] [44] [45] [46] [47] . In spite of some studies have shown that it functions as an oncogene in cancers like Ovarian Cancer and Lung cancer [42, 43] , emerging evidence demonstrated that miR-26a may serve as a potential proliferation, facilitate the apoptosis, inhibit the metastasis ability and reverse the EMT to MET of docetaxel-resistant LAD cells. It was proposed that miR-26a may show critical roles in the progression of docetaxel-resistant LAD cells. EZH2 is a critical component of the polycomb-repressive complex2 (PRC2) which contribute to many essential biological processes. The oncogenic role of EZH2 has recently been documented in several types of cancer [18, 19, 49] . MiR-26a has been reported to suppress tumorgenesis by targeting EZH2 in several tumors [24, 50] . To explore whether EZH2 involved in the miR-26a-mediated function in docetaxel-resistant LAD cells, we detected the expression level of EZH2 in docetaxel-resistant LAD cells and parental cells. Then, qRT-PCR and western blot assays were employed to exam the function of miR-26a on expression of EZH2. Consistent to our assumption, EZH2 is a downstream target of miR-26a and overexpression of miR-26 could remarkably decrease the level of EZH2 in both mRNA and EZH2. To further investigate the role of EZH2 in docetaxel-resistant LAD cells, function suppress the proliferation, facilitate the apoptosis, inhibit the metastasis ability and reverse 
Conclusion
In conclusion, our study demonstrated that miR-26a function as tumor suppressor insight into the molecular pathogenesis of chemoresistant-LAD.
Abbreviations
(hematoxylin and eosin); HMGA2 (High mobility group A2); LAD (lung adenocarcinoma); MEG3 (maternally expressed gene 3); PCNA (proliferating cell nuclear antigen); PRC2 (polycomb-repressive complex2); SDS-PAGE (sodium dodecyl suifate-polyacrylamide gel electrophoresis); siRNA (small interfering RNA); TUNEL (terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling assay). 
